Swedish biotechnology company Cantargia AB (STO:CANTA) on Tuesday released updates on the timelines for the clinical trials of nadunolimab in leukaemia and triple negative breast cancer.

Following US Food and Drug Administration (FDA) approval of a phase 1b/2a clinical trial of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Cantargia estimates that this trial will commence during the fourth quarter of 2024.

"The remaining steps, including IRB review, are currently in process before the trial can be initiated," said Göran Forsberg, Cantargia CEO.

The first results on safety and short-term efficacy in the ongoing phase 2 clinical trial in triple negative breast cancer, in collaboration with GEICAM, are expected during the first half of 2025.